Talaris Therapeutics Inc   (TALS)
Other Ticker:  


Talaris Therapeutics Inc

TALS's Financial Statements and Analysis

Talaris Therapeutics Inc increased III. Quarter net loss per share of $-0.46 compare to net loss per share of $-0.32 recorded in the same quarter a year ago a decrease compare to $-0.44 realized in previous quarter.

III. Quarter
Earnings Per Share Revenues
$ -0.46 $  0 Mill
$-0.14     Unch.    

Talaris Therapeutics Inc 's Revenue fell by 0 % in III. Quarter (Sep 30 2022) year on year, to $0 million and declined by sequentially.

Talaris Therapeutics Inc is Expected to report next financial results on March 16, 2023.

More on TALS's Income Statement

Talaris Therapeutics Inc 's in III. Quarter recorded net loss of $-19.011 million, an increase from net loss of $-12.941 million in III. Quarter a year ago.

Sequentially net loss advanced

More on TALS's Growth

In III. Quarter company's net cash and cash equivalents decreased by $-7 million, capital expenditures grew by -435.12%, to $2 millions compare to same quarter a year ago and rose by -322.80% from II. Quarter (Jun 30 2022).

More on TALS's Cash flow Statement

Talaris Therapeutics Inc does not pay out common stock dividend.

In trailing twelve-month period Talaris Therapeutics Inc payed $ -1.37 cash per share, on a free-cash flow basis .